FGFR3 R248C is an extracellular-domain activating mutation included in the erdafitinib co...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-FGFR3-R248C-UROTHELIAL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-UROTHELIAL |
| Sources | SRC-CIVIC SRC-EAU-BLADDER-2024 SRC-NCCN-BLADDER-2025 |
Actionability Facts
| Biomarker | BIO-FGFR3-MUTATION |
|---|---|
| Variant | R248C |
| Disease | DIS-UROTHELIAL |
| ESCAT tier | IA |
| Recommended combinations | erdafitinib monotherapy |
| Evidence summary | FGFR3 R248C is an extracellular-domain activating mutation included in the erdafitinib companion-diagnostic FGFR alteration panel. Treatment-equivalent to S249C: erdafitinib in 2L+ metastatic urothelial carcinoma per THOR. |
Notes
ESCAT IA. Companion diagnostic includes R248C in the panel.
Used By
No reverse references found in the YAML corpus.